Heart Valve Patent Gets FDA Time Extension Boost
Published Date: 6/16/2025
Notice
Summary
The FDA has set the official review period for the NAVITOR Transcatheter Aortic Valve Implant, a heart device. This helps the company extend its patent, giving them more time to protect their invention. If you’re in medical tech or patent law, watch for this update—it could affect when the device stays exclusive and impacts market competition.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets Review Period for NAVITOR
The FDA has determined the regulatory review period for the NAVITOR Transcatheter Aortic Valve Implant. That determination is being published because the company submitted applications to the U.S. Patent and Trademark Office seeking extension of a patent that claims this medical device, which helps the company seek more time to protect its invention.
Potential Extended Exclusivity and Competition
Because the regulatory review period determination supports a patent extension application, the NAVITOR device could remain under patent protection for a longer time. This could affect when the device stays exclusive and could impact market competition among medical device makers and suppliers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in